CLAIMS

1. A pharmaceutical composition comprising BT8009, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier selected from a buffering agent, a stabilizer or cryoprotectant, and a surfactant.

2. The pharmaceutical composition of claim 1, wherein the buffering agent is histidine.

3. The pharmaceutical composition of claim 1 or 2, wherein the stabilizer or cryoprotectant is sucrose.

4. The pharmaceutical composition of any one of claims 1-3, wherein the surfactant is Polysorbate 20.

5. The pharmaceutical composition of any one of claims 1-4, further comprising a pH adjusting agent.

6. The pharmaceutical composition of claim 5, wherein the pH adjusting agent comprises hydrochloric acid.

7. The pharmaceutical composition of any one of claims 1 -6, which is a solid pharmaceutical composition in lyophilized powder form.

8. The pharmaceutical composition of any one of claims 1-6, which is a liquid pharmaceutical composition further comprising water.

9. The pharmaceutical composition of any one of claims 1-8, comprising:
   BT8009, or a pharmaceutically acceptable salt thereof;
   about 1.31-2.62 mg histidine per mg of BT8009, or a pharmaceutically acceptable thereof;
   about 15-30 mg sucrose per mg of BT8009, or a pharmaceutically acceptable thereof; and
   about 0.05-0.1 mg Polysorbate 20 per mg of BT8009, or a pharmaceutically acceptable thereof.

10. The pharmaceutical composition of claim 9, comprising:
    about 21.2 mg BT8009, or a pharmaceutically acceptable salt thereof;
    about 27.8 mg histidine;
    about 318 mg sucrose; and
    about 1.06 mg Polysorbate 20.

11. The pharmaceutical composition of claim 8, comprising:

about 2-4 mg/mL BT8009, or a pharmaceutically acceptable salt thereof; about 5.24 mg/mL histidine;
about 60 mg/mL sucrose; and
about 0.2 mg/mL Polysorbate 20.

12. Use of the pharmaceutical composition of any one of claims 1-11 in the manufacture of a medicament for treating an advanced solid tumor malignancy associated with Nectin-4-expression in a patient, wherein the pharmaceutical composition is to be intravenously administered to the patient.

13. The use of claim 12, wherein the advanced solid tumor malignancy associated with Nectin-4-expression is selected from the group consisting of non-small-cell lung cancer (NSCLC), ovarian cancer, triple-negative breast cancer (TNBC), gastric/upper gastrointestinal (GI) cancer, pancreatic cancer, and urothelial cancer.

14. The use of claim 12 or 13, wherein the pharmaceutical composition is to be administered once every 7 days.

15. The use of any one of claims 12-14, wherein the pharmaceutical composition is to be administered at a dose of about 2.5, 5.0, 7.5, 10.0, 13.0 or 17.0 mg/m^2.

16. The use of any one of claims 12-15, wherein the pharmaceutical composition is to be administered via an IV infusion of about 60 minutes.

17. The use of any one of claims 12-15, further comprising Nivolumab to be administered to the patient.

18. The use of claim 17, wherein the Nivolumab is to be administered via an IV infusion of about 30 minutes.

19. The pharmaceutical composition according to any one of claims 1-11 for use in therapy.

20. The pharmaceutical composition according to any one of claims 1-11 and Nivolumab for use in therapy.